Drugs / SAIL66
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05735366 | Apr 2023 → Jan 2026 | cancer | Chugai Pharmaceutical | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-24 | Chugai Pharmaceutical | Results Chugai’s SAIL66, under Development for CLDN6 Positive Solid Tumors, Non-Clinical Research Results Published in the Journal for ImmunoTherapy of Cancer chugai-pharm.co.jp ↗
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the results of non-clinical research on SAIL66, a Chugai’s in-house project under Phase I clinical development for CLDN6 positive solid tumors, have been published in the Journal for ImmunoTherapy of Cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-24 | Chugai Pharmaceutical | Chugai’s SAIL66, under Development for CLDN6 Positive Solid Tumors, Non-Clinical Research Results Published in the Journal for ImmunoTherapy of Cancer chugai-pharm.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAIL66 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05735366 ↗ |
| Route | Intravenous | “SAIL66 as a IV infusion” NCT05735366 ↗ |